Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 7 Summary measures for eight (L1-L8) fingertip blood lactate analyses (mmol/L) from tests of upper body power

From: Influence of an alkalizing supplement on markers of endurance performance using a double-blind placebo-controlled design

  Constant-Power Test UBP10 Tests UBP60 Test
Group †L1 L2 Trial #1
L3
Trial #2
L4
Trial #3
L5
L6 L7 L8
Placebo
Pre-Testing
Post-Testing
5.3 ± 0.6
4.9 ± 0.6
5.0 ± 0.6
5.0 ± 0.7
5.1 ± 0.6
4.9 ± 0.6
5.6 ± 0.5
5.6 ± 0.5
6.4 ± 0.6
6.6 ± 0.5
9.2 ± 0.5
9.4 ± 0.5
9.8 ± 0.6
10.3 ± 0.6
9.7 ± 0.6
‡10.3 ± 0.6
Treatment
Pre-Testing
Post-Testing
7.0 ± 0.6
‡5.5 ± 0.6
5.8 ± 0.8
5.7 ± 0.7
6.1 ± 0.7
5.6 ± 0.7
6.6 ± 0.6
6.3 ± 0.6
7.2 ± 0.6
7.2 ± 0.7
9.8 ± 0.8
9.4 ± 0.7
10.9 ± 0.7
‡9.8 ± 0.7
10.4 ± 0.7
‡9.4 ± 0.6
  1. NOTE: All values expressed as Mean ± SE; UBP10 = 10-sec upper body power test; UBP60 = 60-sec upper body power test. Sample sizes remained at 12 subjects per group for both pre- and post-testing
  2. †The eight blood lactate samples (L1-L8) are labeled the same as those shown within Figure 1
  3. ‡Mean post-testing blood lactate value differed significantly (P < 0.05) from corresponding pre-testing value within the same test group